MK-2870
MK-2870 or SKB264 is an experimental antibody–drug conjugate. The antibody component is directed against "the trophoblast cell-surface antigen 2 (TROP2), which is overexpressed in many types of solid tumors, coupled to moderate cytotoxic belotecan-derivative through a novel linker which was designed to balance the extracellular stability and intracellular rupture".[1][2][3] The drug is developed as a partnership between Merck and the Chinese company Kelun.[4]
References[edit]
- ^ Rodon, J.; Li, J.; Xue, J.; Diao, Y.; Xu, Y.; Liu, G.; Rao, C.; Fan, B.; Cheng, Y.; Wang, J. (September 2021). "514O An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors". Annals of Oncology. 32: S585. doi:10.1016/j.annonc.2021.08.1036.
- ^ Ouyang, Q.; Yin, Y.; Song, L.; Yan, M.; Wu, X.; Tong, Z.; Liu, Y.; Wang, X.; Jin, X.; Diao, Y.; Liu, G.; Ge, J.; Li, J. (October 2023). "380MO SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): Results from a phase I/II, single-arm, basket trial". Annals of Oncology. 34: S337. doi:10.1016/j.annonc.2023.09.557.
- ^ Yin, Yongmei; Wu, Xinhong; Ouyang, Quchang; Yan, Min; Song, Lihua; Liu, YunPeng; Tong, Zhongsheng; Geng, Cuizhi; Wang, Ying; Yu, Guohua; Wang, Xiang; Cheng, Ying; Zhao, Weihong; Li, Qun; Diao, Yina; Liu, Gesha; Ge, Junyou; Li, Jin (1 March 2023). "Abstract OT1-03-02: Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Phase 2 study". Cancer Research. 83 (5_Supplement): OT1–03–02-OT1-03-02. doi:10.1158/1538-7445.SABCS22-OT1-03-02.
- ^ Taylor, Nick Paul. "Merck trims mushrooming ADC pipeline by pulling out of 2 preclinical Kelun programs". Fierce Biotech. Retrieved 20 November 2023.